- Home
- ONFO vs KZIA Comparison
ONFO vs KZIA Comparison
Compare ONFO & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONFO
- KZIA
- Stock Information
- Founded
- ONFO 2018
- KZIA 1994
- Country
- ONFO United States
- KZIA Australia
- Employees
- ONFO N/A
- KZIA N/A
- Industry
- ONFO Computer Software: Programming Data Processing
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- ONFO Technology
- KZIA Health Care
- Exchange
- ONFO Nasdaq
- KZIA Nasdaq
- Market Cap
- ONFO 6.2M
- KZIA 6.0M
- IPO Year
- ONFO 2022
- KZIA 1999
- Fundamental
- Price
- ONFO $1.23
- KZIA $0.96
- Analyst Decision
- ONFO
- KZIA Strong Buy
- Analyst Count
- ONFO 0
- KZIA 2
- Target Price
- ONFO N/A
- KZIA $11.50
- AVG Volume (30 Days)
- ONFO 22.2K
- KZIA 384.7K
- Earning Date
- ONFO 11-15-2024
- KZIA 03-26-2025
- Dividend Yield
- ONFO N/A
- KZIA N/A
- EPS Growth
- ONFO N/A
- KZIA N/A
- EPS
- ONFO N/A
- KZIA N/A
- Revenue
- ONFO $6,590,171.00
- KZIA $1,655,324.00
- Revenue This Year
- ONFO $133.59
- KZIA N/A
- Revenue Next Year
- ONFO N/A
- KZIA N/A
- P/E Ratio
- ONFO N/A
- KZIA N/A
- Revenue Growth
- ONFO 29.25
- KZIA 248000.00
- 52 Week Low
- ONFO $0.39
- KZIA $0.76
- 52 Week High
- ONFO $1.88
- KZIA $15.80
- Technical
- Relative Strength Index (RSI)
- ONFO 47.15
- KZIA 44.72
- Support Level
- ONFO $1.11
- KZIA $0.86
- Resistance Level
- ONFO $1.32
- KZIA $0.99
- Average True Range (ATR)
- ONFO 0.09
- KZIA 0.13
- MACD
- ONFO -0.01
- KZIA 0.06
- Stochastic Oscillator
- ONFO 43.64
- KZIA 29.41
About ONFO Onfolio Holdings Inc.
Onfolio Holdings Inc actively manages small online businesses that operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by existing teams or have management teams largely in place.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.